Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04020276 · ClinicalTrials.gov registry record · NA
OAR-Based, Dose Escalated SBRT With Real Time Adaptive MRI Guidance for Liver Metastases
A NA study of Liver Metastases and Stereotactic Body Radiation Therapy, sponsored by University of Wisconsin, Madison.
- Recruiting
- Registry status
- NA
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT04020276: Recruiting NA study of Liver Metastases and Stereotactic Body Radiation Therapy, sponsored by University of Wisconsin, Madison.
NCT04020276 is a NA study of Liver Metastases and Stereotactic Body Radiation Therapy that is actively recruiting participants, run by University of Wisconsin, Madison. The registered enrollment target is 32 participants, below the 67-participant average among 27 other Liver Metastases trials with a reported enrollment target (52% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04020276, a NA study of Liver Metastases and Stereotactic Body Radiation Therapy, is actively recruiting participants, sponsored by University of Wisconsin, Madison.
- RECRUITING
- Registry status
- NA
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this trial is to identify a safe maximum tolerated dose level for MRI-guided Stereotactic Body Radiation Therapy (SBRT) treatment of bowel and liver metastases, respectively. Eligible participants will be on study for up to 12 months.
Primary Outcome
Dose limiting toxicity (DLT) will be defined as grade 3 or greater\* non-hematologic toxicity attributable to radiation therapy, and occurring within 4 weeks after the completion of SBRT. \*With the exception of liver function tests, which are allowed up to and including grade 3
Conditions Studied
Interventions
- RADIATION SBRT
Study Locations (1)
Wisconsin
- University of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2019-11-04 |
| Est. Completion | 2028-12 |
| Phase | NA |
What NCT04020276 shows while recruiting
NCT04020276 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 67-participant average among 27 other Liver Metastases trials with a reported enrollment target (52% lower).
The record links to 3 conditions, with Liver Metastases appearing as the primary indexed condition, and to 1 intervention - of which SBRT is the first listed.
NCT04020276 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT04020276 about?
NCT04020276 is a clinical study titled "OAR-Based, Dose Escalated SBRT With Real Time Adaptive MRI Guidance for Liver Metastases". The purpose of this trial is to identify a safe maximum tolerated dose level for MRI-guided Stereotactic Body Radiation Therapy (SBRT) treatment of bowel and liver metastases, respectively. Eligible participants will be on study for up to 12 months.
What is the current status of trial NCT04020276?
This trial is currently recruiting. It is a NA study. The enrollment target is 32 participants. The study started on 2019-11-04. Estimated completion is 2028-12.
What conditions does trial NCT04020276 study?
This clinical trial studies the following conditions: Liver Metastases, Stereotactic Body Radiation Therapy, MRI-guided Treatment.
What interventions are being tested in trial NCT04020276?
The interventions under investigation include: SBRT (RADIATION).
Who is sponsoring clinical trial NCT04020276?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04020276 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Metastases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04020276's enrollment target sits among peer trials
32 14th of 27 higher than 13 of 27 other Liver Metastases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Liver Metastases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Promoting Immunotherapy Efficacy With Low-Dose Liver RT
RECRUITING · NA
-
Stereotactic Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
-
Histotripsy Plus Chemotherapy vs Chemotherapy Alone for Advanced Colorectal Liver Metastasis
RECRUITING · NA
-
HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer
RECRUITING · NA
-
Proton Therapy in the Treatment of Liver Metastases
RECRUITING · NA
-
Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI